Drug Approval | March 02, 2022
Amneal enters U.S. biosimilars market with approval of Releukotm
First of three Amneal biosimilars expected for U.S. approval and launch in 2022
First of three Amneal biosimilars expected for U.S. approval and launch in 2022
Pegfilgrastim is indicated to reduce the duration of neutropenia and the incidence of febrile neutropenia in patients receiving chemotherapy
Lupin had earlier received the U.S. FDA acceptance of the Biologics License Application (BLA) for Its proposed biosimilar
Gavreto is the first and only precision medicine approved in the EU for first-line treatment of people with RET fusion-positive advanced NSCLC
posaconazole delayed-release tablets 100 mg are the generic equivalent of Noxafil.
Subscribe To Our Newsletter & Stay Updated
